Pharma News

Indian scientists receive award for remarkable research

  • Posted on: 10 January 2020
  • By: PharmaTutor News

Indian researchers have received first Merck Young Scientist Award 2019 in Chemical Sciences recently at Bangalore instituted by Merck, a science and technology company operating worldwide. Merck Young Scientist Award is given to researchers with less than ten years of experience with expertise in solving some of the toughest problems in chemical sciences.

Zinc, folic acid supplement does not improve male fertility, NIH study suggests

  • Posted on: 9 January 2020
  • By: Shalini.Sharma

Dietary supplements containing zinc and folic acid — marketed as a treatment for male infertility — do not appear to improve pregnancy rates, sperm counts or sperm function, according to a study conducted by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health. The study appears in the Journal of the American Medical Association.

New multiple sclerosis treatment trial compares stem cell transplantation to best available drugs

  • Posted on: 9 January 2020
  • By: Shalini.Sharma

A clinical trial has begun testing an experimental stem cell treatment against the best available biologic therapies for severe forms of relapsing multiple sclerosis (MS). The trial, sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will compare the safety, efficacy and cost-effectiveness of the two therapeutic approaches.

Merck Establishes Strategic Oncology Collaboration with Taiho and Astex

  • Posted on: 7 January 2020
  • By: PharmaTutor News

MSD outside the United States and Canada, announced an exclusive worldwide research collaboration and license agreement with Taiho Pharmaceutical Co, Ltd., (“Taiho”) and Astex Pharmaceuticals (UK), a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd. (“Astex”), focused on the development of small molecule inhibitors against several drug targets, including the KRAS oncogene, which are currently being investigated for the treatment of cancer.

Glenmark Pharmaceuticals receives ANDA approval for Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg

  • Posted on: 7 January 2020
  • By: PharmaTutor News

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (U.S.FDA) for Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, the generic version of Exjade®1 Tablets for Oral Suspension, 125 mg, 250 mg and 500 mg, of Novartis Pharmaceuticals Corporation.

Fycompa for Adjunctive treatment of Partial Onset Seizures launched in China

  • Posted on: 6 January 2020
  • By: PharmaTutor News

Eisai Co., Ltd announced today that it has launched the in-house discovered and developed antiepileptic drug (AED) Fycompa®,  generic name perampanel) for use in adjunctive treatment of partial onset seizures (with or without secondarily generalized seizures) in epilepsy patients 12 years of age and older.

Using gene therapy to treat chronic traumatic encephalopathy

  • Posted on: 4 January 2020
  • By: PharmaTutor News

A new study shows the feasibility of using gene therapy to treat the progressive neurodegenerative disorder chronic traumatic encephalopathy (CTE). The study, which demonstrated the effectiveness of direct delivery of gene therapy into the brain of a mouse model of CTE, is published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

Pages